Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Oxaliplatin + Resminostat|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Oxaliplatin||Eloxatin||Diaminocyclohexane Oxalatoplatinum||Chemotherapy - Platinum 6||Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).|
|Resminostat||4SC-201||HDAC Inhibitor 38||Resminostat (4SC-201) is a histone deacetylase inhibitor that induces chromatin remodeling, leading to growth inhibition and apoptosis in tumor cells (PMID: 20201941).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Oxaliplatin + Resminostat||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of Resminostat (4SC-201) and Eloxatin (oxaliplatin) induced apoptosis in a colorectal cancer (CRC) cell line and primary colon cancer cells in culture, and inhibited tumor growth in a CRC cell line xenograft model, with increased activity compared to either agent alone (PMID: 26831668).||26831668|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|